Baron Wealth Management LLC Sells 70 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Baron Wealth Management LLC reduced its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,117 shares of the company’s stock after selling 70 shares during the period. Baron Wealth Management LLC’s holdings in Medpace were worth $371,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company lifted its position in shares of Medpace by 0.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,129 shares of the company’s stock worth $8,702,000 after purchasing an additional 94 shares during the last quarter. Mackenzie Financial Corp bought a new stake in shares of Medpace in the second quarter valued at approximately $747,000. Northwestern Mutual Wealth Management Co. boosted its position in shares of Medpace by 95.7% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 225 shares of the company’s stock valued at $93,000 after acquiring an additional 110 shares during the period. Truist Financial Corp grew its stake in shares of Medpace by 21.2% in the second quarter. Truist Financial Corp now owns 3,700 shares of the company’s stock worth $1,524,000 after acquiring an additional 648 shares during the last quarter. Finally, Cetera Investment Advisers increased its position in Medpace by 2.3% during the second quarter. Cetera Investment Advisers now owns 11,757 shares of the company’s stock worth $4,842,000 after acquiring an additional 263 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Trading Down 0.8 %

Shares of Medpace stock opened at $343.02 on Thursday. The firm’s 50-day moving average price is $341.77 and its two-hundred day moving average price is $353.45. Medpace Holdings, Inc. has a 1-year low of $286.76 and a 1-year high of $459.77. The stock has a market capitalization of $10.66 billion, a price-to-earnings ratio of 30.04, a P/E/G ratio of 1.77 and a beta of 1.36.

Analyst Ratings Changes

Several analysts have issued reports on MEDP shares. William Blair restated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Truist Financial decreased their target price on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Redburn Atlantic initiated coverage on Medpace in a report on Monday, October 14th. They set a “buy” rating and a $404.00 price objective on the stock. TD Cowen lowered their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Finally, Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and an average target price of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.